AI assistant
Dechra Pharmaceuticals PLC Director's Dealing 2022
4797_dirs_2022-09-26_3ec8de0a-5394-4f77-8291-6e2d9604da8b.html
Director's Dealing
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information 
RNS Number : 6798A
Dechra Pharmaceuticals PLC
26 September 2022
26 September 2022
Dechra® Pharmaceuticals PLC
(Dechra or the Company)
Notification and public disclosure of transactions by
persons discharging managerial responsibilities (PDMRs)
Dechra Pharmaceuticals PLC announces that on 23 September 2022, it was notified that on 22 September 2022, the following PDMRs sold the shares set out below (acquired pursuant to the Dechra Pharmaceuticals PLC Long Term Incentive Plan (the LTIP) exercise/vesting announced on 22 September 2022) in order to fund the resulting tax liability. In accordance with the Company's Directors' Remuneration Policy, the remaining shares must be retained for a period of two years from the date of vesting.
| Name | Capacity | Shares Sold |
Sale Price per share |
Total beneficial shareholding following this announcement | Percentage of issued share capital |
| Ian Page | Director | 10,834 | £27.808 | 404,535 | 0.36% |
| Paul Sandland | Director | 1,936 | £27.808 | 11,714 | 0.01% |
| Tony Griffin | Director | 3,608 | £27.808 | 37,049 | 0.03% |
The Notification of Dealing Forms set out below are provided in accordance with the requirements of the UK Market Abuse Regulation.
Notification of Dealing Forms
| 1. | Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") |
||
| a) | Name | Ian Page | |
| 2. | Reason for the notification | ||
| a) | Position/status | Director/PDMR | |
| b) | Initial notification/ amendment |
Initial Notification | |
| 3. | Details of the Issuer | ||
| a) | Name | Dechra Pharmaceuticals PLC | |
| b) | LEI code | 213800J4UVB5OWG8VX82 | |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument Identification code |
Ordinary Shares of 1 pence each ISIN: GB0009633180 |
|
| b) | Nature of the transaction | Partial sale of shares obtained under the Company's Long Term Incentive Plan to satisfy tax liability | |
| c) | Price(s) and volumes(s) | Price(s) £27.807816 |
Volume(s) 10,834 |
| d) | Aggregated information - Aggregate volume - Price - Total |
10,834 £27.807816 £301,269.88 |
|
| e) | Date of the transaction | 2022.09.22 | |
| f) | Place of the transaction | London Stock Exchange |
| 1. | Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") |
||
| a) | Name | Paul Sandland | |
| 2. | Reason for the notification | ||
| a) | Position/status | Director/PDMR | |
| b) | Initial notification/ amendment |
Initial Notification | |
| 3. | Details of the Issuer | ||
| a) | Name | Dechra Pharmaceuticals PLC | |
| b) | LEI code | 213800J4UVB5OWG8VX82 | |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument Identification code |
Ordinary Shares of 1 pence each ISIN: GB0009633180 |
|
| b) | Nature of the transaction | Partial sale of shares obtained under the Company's Long Term Incentive Plan to satisfy tax liability | |
| c) | Price(s) and volumes(s) | Price(s) £27.807816 |
Volume(s) 1,936 |
| d) | Aggregated information - Aggregate volume - Price - Total |
1,936 £27.807816 £53,835.93 |
|
| e) | Date of the transaction | 2022.09.22 | |
| f) | Place of the transaction | London Stock Exchange |
| 1. | Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") |
||
| a) | Name | Tony Griffin | |
| 2. | Reason for the notification | ||
| a) | Position/status | Director/PDMR | |
| b) | Initial notification/ amendment |
Initial Notification | |
| 3. | Details of the Issuer | ||
| a) | Name | Dechra Pharmaceuticals PLC | |
| b) | LEI code | 213800J4UVB5OWG8VX82 | |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument Identification code |
Ordinary Shares of 1 pence each ISIN: GB0009633180 |
|
| b) | Nature of the transaction | Partial sale of shares obtained under the Company's Long Term Incentive Plan to satisfy tax liability | |
| c) | Price(s) and volumes(s) | Price(s) £27.807816 |
Volume(s) 3,608 |
| d) | Aggregated information - Aggregate volume - Price - Total |
3,608 £27.807816 £100,330.60 |
|
| e) | Date of the transaction | 2022.09.22 | |
| f) | Place of the transaction | London Stock Exchange |
For further information, please contact:
Melanie Hall, Company Secretary
Telephone: 01606 814730
About Dechra
Dechra is a global specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. For more information please visit: www.dechra.com.
Trademarks
Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHBXGDCCUDDGDL